Show simple item record

dc.contributor.authorFarah, Shady
dc.contributor.authorGreiner, Dale L.
dc.contributor.authorAnderson, Daniel G.
dc.date2022-08-11T08:10:18.000
dc.date.accessioned2022-08-23T17:03:19Z
dc.date.available2022-08-23T17:03:19Z
dc.date.issued2019-08-01
dc.date.submitted2019-10-07
dc.identifier.citation<p>Nat Mater. 2019 Aug;18(8):892-904. doi: 10.1038/s41563-019-0377-5. Epub 2019 Jun 24. <a href="https://doi.org/10.1038/s41563-019-0377-5">Link to article on publisher's site</a></p>
dc.identifier.issn1476-1122 (Linking)
dc.identifier.doi10.1038/s41563-019-0377-5
dc.identifier.pmid31235902
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44398
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractImplantable medical devices have revolutionized modern medicine. However, immune-mediated foreign body response (FBR) to the materials of these devices can limit their function or even induce failure. Here we describe long-term controlled-release formulations for local anti-inflammatory release through the development of compact, solvent-free crystals. The compact lattice structure of these crystals allows for very slow, surface dissolution and high drug density. These formulations suppress FBR in both rodents and non-human primates for at least 1.3 years and 6 months, respectively. Formulations inhibited fibrosis across multiple implant sites-subcutaneous, intraperitoneal and intramuscular. In particular, incorporation of GW2580, a colony stimulating factor 1 receptor inhibitor, into a range of devices, including human islet microencapsulation systems, electrode-based continuous glucose-sensing monitors and muscle-stimulating devices, inhibits fibrosis, thereby allowing for extended function. We believe that local, long-term controlled release with the crystal formulations described here enhances and extends function in a range of medical devices and provides a generalized solution to the local immune response to implanted biomaterials.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=31235902&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1038/s41563-019-0377-5
dc.subjectBiomedical engineering
dc.subjectDrug delivery
dc.subjectImplants
dc.subjectTranslational research
dc.subjectBiochemistry
dc.subjectBiomaterials
dc.subjectBiomedical Devices and Instrumentation
dc.subjectImmunopathology
dc.subjectImmunoprophylaxis and Therapy
dc.subjectMolecular Biology
dc.subjectTherapeutics
dc.subjectTranslational Medical Research
dc.titleLong-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations
dc.typeJournal Article
dc.source.journaltitleNature materials
dc.source.volume18
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/pmm_pp/132
dc.identifier.contextkey15503632
html.description.abstract<p>Implantable medical devices have revolutionized modern medicine. However, immune-mediated foreign body response (FBR) to the materials of these devices can limit their function or even induce failure. Here we describe long-term controlled-release formulations for local anti-inflammatory release through the development of compact, solvent-free crystals. The compact lattice structure of these crystals allows for very slow, surface dissolution and high drug density. These formulations suppress FBR in both rodents and non-human primates for at least 1.3 years and 6 months, respectively. Formulations inhibited fibrosis across multiple implant sites-subcutaneous, intraperitoneal and intramuscular. In particular, incorporation of GW2580, a colony stimulating factor 1 receptor inhibitor, into a range of devices, including human islet microencapsulation systems, electrode-based continuous glucose-sensing monitors and muscle-stimulating devices, inhibits fibrosis, thereby allowing for extended function. We believe that local, long-term controlled release with the crystal formulations described here enhances and extends function in a range of medical devices and provides a generalized solution to the local immune response to implanted biomaterials.</p>
dc.identifier.submissionpathpmm_pp/132
dc.contributor.departmentProgram in Molecular Medicine
dc.source.pages892-904


This item appears in the following Collection(s)

Show simple item record